Adocia climbs on fast-acting insulin data

Adocia S.A. (Euronext:ADOC) rose EUR 9.62 (15%) to EUR 73.40 after the company's HinsBet fast-acting insulin met the primary endpoint of an increase in recombinant human insulin bioavailability during the first hour after dosing compared to Humulin from Eli Lilly and Co. (NYSE:LLY) in a Phase IIa trial to treat Type I diabetes.

HinsBet led to a 70% increase in early insulin exposure during the first hour post-dosing (p<0.0001) among 36 Type I diabetes patients receiving single 0.2 U/kg doses of HinsBet, Humulin and Lilly's Humalog. In the crossover study, patients received all three treatments in a random order. Compared to Humulin, HinsBet also had a 70% shorter onset of action (p<0.0001) and led to a metabolic effect twice as large as that of Humulin during the first hour after dosing (p<0.0001). There was no significant difference in total insulin exposure between HinsBet and Humulin. HinsBet's absorption rate and metabolic effect were similar to Humalog's. ...